<bill session="113" type="s" number="77" updated="2013-11-02T06:52:51-04:00">
  <state datetime="2013-01-23">REFERRED</state>
  <status>
    <introduced datetime="2013-01-23"/>
  </status>
  <introduced datetime="2013-01-23"/>
  <titles>
    <title type="short" as="introduced">Prescription Drug and Health Improvement Act of 2013</title>
    <title type="official" as="introduced">A bill to amend part D of title XVIII of the Social Security Act to authorize the Secretary of Health and Human Services to negotiate for lower prices for Medicare prescription drugs.</title>
  </titles>
  <sponsor id="412378"/>
  <cosponsors>
    <cosponsor id="400050" joined="2013-03-05"/>
    <cosponsor id="412242" joined="2013-01-23"/>
  </cosponsors>
  <actions>
    <action datetime="2013-01-23" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
    <term name="Public contracts and procurement"/>
  </subjects>
  <amendments/>
  <summary>1/23/2013--Introduced.
Prescription Drug and Health Improvement Act of 2013 - Amends title XVIII (Medicare) of the Social Security Act (SSA) with respect to prescription drug plans to repeal the prohibition against: (1) interference by the Secretary of Health and Human Services (HHS) with negotiations between drug manufacturers and pharmacies and prescription drug plan sponsors, and (2) requiring a particular formulary or instituting a price structure for the reimbursement of covered part D (Voluntary Prescription Drug Benefit Program) drugs. Grants the Secretary authority similar to that of other federal entities that purchase prescription drugs in bulk to negotiate contracts with manufacturers of covered part D drugs.</summary>
</bill>
